Japan Lung Cancer Therapeutics Market Report 2022 to 2030

Japan Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Japan Lung Cancer Therapeutics Market will reach a value of $3.5 Bn from $1.8 Bn in 2022, growing at a CAGR of 8.6% during 2022-2030. The Lung Cancer Therapeutics Market in Japan is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Ono Pharmaceutical. The Lung Cancer Therapeutics Market in Japan is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Japanese lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10JPPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Japan Lung Cancer Therapeutics market will reach a value of $3.5 Bn from $1.8 Bn in 2022, growing at a CAGR of 8.6% during 2022-2030.

Japan is a high-income developed island nation in East Asia. In 2019, lung cancer was the leading cause of death among all cancers, followed by colorectal cancer and stomach cancer. Men died from lung cancer at a rate of 53,200 per 100,000, while women died at a rate of 22,300 per 100,000. Ageing also plays a role in this predicament, as age-adjusted death rates have been declining since peaking in the 1990s. Japan is one of the few countries in the world where systemic cancer therapy is available to all residents, regardless of money or geographic location. Japan is likely to lead the globe in increasing the cure rate of patients with driver gene mutations like EGFR and ALK.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Japan reached 79,688 or 7.21% of total deaths. The age-adjusted Death Rate is 18.06 per 100,000 population ranks Japan 66^th in the world. Japan's government spends 10.3% of its GDP on healthcare.

Japan Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

According to the Japanese Society for Radiation Oncology's 2017 Japanese Structure Survey of Radiation Oncology, radiation treatment was used to treat a total of 185,523 patients, including 30,870 patients (16.6 %) with lung cancer (RT). The Japanese Joint Committee of Lung Cancer Registry performs nationwide surveys of lung cancer surgery regularly. Japan is home to cutting-edge technologies and a broad manufacturing base. These aspects could boost Japan's Lung Cancer Therapeutics market.

Market Restraints

There are 1322 board-certified radiation oncologists and 1337 board-certified medical physicists working in Japan as of 2021, however, there is still a considerable shortage of these specialists, particularly in small-scale facilities. Lung cancer in non-smokers is a thoracic oncology concern in Japan. It is generally known that the prevalence of non-smoking lung cancer, such as EGFR mutation-positive lung cancer, is high in Japan. In Japan, while smoking rates are decreasing, the frequency of lung cancer among non-smokers is among the highest in the world. Japan is having a labour shortage as well as a low contribution from immigration, which is increasing the number of insecure workers. These factors may deter new entrants into the Japan Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Chugai Pharmaceutical: Chugai Pharmaceutical is a leading Japanese pharmaceutical company that is focused on the development and commercialization of innovative medicines for cancer and other serious diseases, including lung cancer
Taiho Pharmaceutical: Taiho Pharmaceutical is a Japanese pharmaceutical company that develops and sells a range of cancer treatments, including those used in the treatment of lung cancer
Ono Pharmaceutical: Ono Pharmaceutical is a Japanese pharmaceutical company that develops and sells a range of medicines, including those used in the treatment of cancer, such as lung cancer
Eisai: Eisai is a Japanese pharmaceutical company that develops and sells a range of medicines, including those used in the treatment of cancer, such as lung cancer
Takeda Pharmaceutical Company Limited: Takeda Pharmaceutical Company is a Japanese multinational pharmaceutical company that is focused on developing and commercializing innovative medicines for patients around the world, including those with lung cancer
Otsuka Pharmaceutical: Otsuka Pharmaceutical is a Japanese pharmaceutical company that develops and sells a range of medicines, including those used in the treatment of cancer, such as lung cancer

Recent Notable Updates

May 2022: Chugai Pharmaceutical announced that the Ministry of Health, Labour, and Welfare approved an additional indication for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq Intravenous Infusion 1200 mg for the adjuvant treatment of PD-L1-positive non-small cell lung cancer (NSCLC). To identify PD-L1 expression, Roche Diagnostics K.K.'s VENTANA OptiView PD-L1 pathological diagnostic kit should be used. In May 2022, the FDA approved the extended use of this test kit as a companion diagnostic for Tecentriq, allowing clinicians to identify patients with PD-L1-positive NSCLC who potentially benefit from Tecentriq.

Healthcare Policies and Reimbursement Scenarios

The Ministry of Health, Labour, and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency regulate the regulation and reimbursement of lung cancer therapies in Japan (PMDA). The Ministry of Health, Labour, and Welfare issues Pharmaceuticals and Medical Devices Safety Information (PMDSI) based on safety data gathered. It is meant to help healthcare workers handle medications and medical devices more safely. The Central Social Insurance Medical Body (Chuikyo), an advisory council of medical and other specialists, makes recommendations to the MHLW.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.